# US 8,772,333 B2 · Fumigillol type compounds and methods of making and using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,772,333 B2
- Document ID: US8772333B2
- Status: Granted
- Kind: B2
- Application number: 13/520,736
- Filed: 2011-01-07
- Published: 2013-01-17
- Granted: 2014-07-08
- Earliest claimed: 2010-01-08
- Assignees: Zafgen, Inc.
- Applicants: James E. Vath
- Inventors: James E. Vath
- Web page: https://patentgrep.com/patent/US8772333B2

## CPC

- A61K 31/336: having three-membered rings, e.g. oxirane, fumagillin
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 303/16: by esterified hydroxyl radicals
- C07D 407/04: directly linked by a ring-member-to-ring-member bond
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The disclosure provides a fumagillol type compound and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of using, e.g. in the treatment of obesity are provided.

## Claims

### Claim 1

A method of treating and/or controlling obesity, comprising administering to a patient in need thereof an effective amount of the compound represented by
or pharmaceutically acceptable salts or stereoisomers thereof.

### Claim 2

A method of inducing weight loss in a patient in need thereof, comprising administering to said patient an effective amount of the compound represented by
or pharmaceutically acceptable salts or stereoisomers thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the patient is a human.

### Claim 4 (depends on 1)

The method of claim 1, wherein the patient has a body mass index greater than or equal to about 25 kg/m2 before the administration.

### Claim 5 (depends on 1)

The method of claim 1, wherein the compound is administered orally, intravenously, or subcutaneously.